News Headlines

  1. Flexion Therapeutics Sponsors A Memorial To The Victims Of The Opioid Crisis To Raise Awareness Of The Tragic Consequences Of The Opioid Epidemic Across The U.S.
    9/23/2019

    Flexion Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), recently announced its sponsorship of “Prescribed to Death: A Memorial to the Victims of the Opioid Crisis.”

  2. Firma Clinical Research And The Myositis Association Join Forces To Enhance Clinical Trial Patient Care Partner Training
    9/23/2019

    Firma Clinical Research, a niche service provider, is partnering with The Myositis Association (TMA) on a multi-faceted project to better integrate the experience of patients into the training of clinical trial investigators and support providers.

  3. Foamix Announces Enrollment Of First Patient In Phase 2 Acne Clinical Trial For FCD105 Minocycline 3% And Adapalene 0.3% Combination Foam
    9/20/2019

    Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate the efficacy and safety of its topical combination foam, comprised of minocycline 3% and adapalene 0.3%, FCD105 for the treatment of moderate-to-severe acne vulgaris.

  4. ZS Launches Clinical Design Center To Help Accelerate Clinical Programs And New Therapies To Patients Faster
    9/19/2019

    Global professional services firm ZS has launched Clinical Design Center, an integrated technology platform and services solution that allows cross-functional teams within pharmaceutical organizations to collaborate in a virtual environment to make better data-driven decisions on clinical trial design and operations. It allows teams to gain more clarity into clinical trials' likely challenges and outcomes, increase efficiency and accelerate clinical programs—ultimately getting new and better therapies to patients more quickly.

  5. Health Decisions Receives 4th Consecutive Appointment As Statistical And Clinical Coordinating Center For The Contraceptive Clinical Trials Network Of The NICHD
    9/17/2019

    Health Decisions, Inc., a full-service contract research organization specializing in women’s health clinical research and diagnostic development, announced that it has been retained as the Statistical and Clinical Coordinating Center (SCCC) for the Contraceptive Clinical Trials Network (CCTN) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a unit of the National Institutes of Health (NIH).

  6. Interpace Enters Strategic Partnership Agreement With Genecast Biotechnology To Partner With Biopharma Solutions In China
    9/16/2019

    Interpace Diagnostics Group, Inc.’s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”).

  7. Kura Oncology Doses First Patient In Phase 1 Clinical Trial Of Menin-MLL Inhibitor KO-539 In Acute Myeloid Leukemia
    9/16/2019

    Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in a Phase 1 clinical trial of KO-539, the Company’s first-in-class inhibitor of the menin-mixed lineage leukemia (menin-MLL) interaction, in patients with relapsed or refractory acute myeloid leukemia (AML).

  8. Sharp’s Netherlands Facility Approved for Clinical Operations
    9/12/2019

    Sharp - part of UDG Healthcare plc, a global leader in contract packaging and clinical supply services, has received Wholesale Distribution Authorisation (WDA) and Investigational Medicinal Product (IMP) licensing approvals to support clinical activities from its facility in Heerenveen, Netherlands. 

  9. Momotaro-Gene Announces First Patient Dosed In Phase 2 Clinical Trial Of MTG201 In Combination With Nivolumab In Patients With Relapsed Malignant Pleural Mesothelioma
    9/11/2019

    Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of the first patient in a Phase 2 clinical trial combining MTG201, the company’s lead therapeutic candidate, with the PD-1 inhibitor nivolumab (Opdivo®) in patients with relapsed malignant pleural mesothelioma.

  10. More Emerging Biopharma And CROs Adopting Veeva Vault CDMS
    9/9/2019

    An increasing number of emerging biopharma companies and leading contract research organizations (CROs) are adopting Vault CDMS from Veeva Systems (NYSE:VEEV) to manage their clinical data. More life sciences organizations are using Veeva Vault CDMS for multiple clinical trials to drive greater speed and agility in study execution.